Benjamin T. Dake - Dec 14, 2021 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Dec 14, 2021
Transactions value $
$0
Form type
4
Date filed
12/16/2021, 05:00 PM
Previous filing
Jun 29, 2021
Next filing
Aug 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +58K $0.00 58K Dec 14, 2021 Common Stock 58K $10.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary